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ABSTRAK
Latar belakang: inflamasi kronik derajat rendah pada obesitas menyebabkan abnormalitas lipid dan 
resistensi insulin. Vitamin E mempunyai efek antioksidan dan dapat meningkatkan sensitivitas insulin dengan 
perantara adiponektin. Penelitian ini bertujuan untuk menilai efek suplementasi vitamin E terhadap profil lipid 
dan kadar adiponektin pada remaja dengan obesitas. Metode: penelitian ini merupakan uji klinis acak tersamar 
ganda. Remaja obesitas berusia 14-18 tahun tanpa riwayat konsumsi obat-obatan antiobesitas atau antioksidan 
diikutsertakan dalam penelitian ini. Mereka dibagi menjadi dua kelompok menggunakan metode randomisasi: 
kelompok vitamin E dan plasebo. Dosis vitamin E yang digunakan adalah 400 IU/hari. Intervensi diberikan 
selama 2 bulan. Profil lipid dan kadar adiponektin diukur sebelum dan setelah pemberian intervensi. Hasil utama 
dianalisis menggunakan prinsip “per-protocol analysis”. Analisis statistik menggunakan uji t independen, dan 
uji Mann-Whitney U sebagai alternatifnya. Hasil: sebanyak 66 subyek menyelesaikan penelitian, terdiri dari 
34 subyek pada kelompok vitamin E dan 32 subyek pada kelompok plasebo. Profil lipid dan kadar adiponektin 
setelah intervensi selama 2 bulan tidak berbeda bermakna antara kedua kelompok. Perubahan parameter-
parameter tersebut dari nilai dasar juga tidak berbeda bermakna antara kedua kelompok dan tidak konsisten 
dari satu subyek ke subyek lainnya. Kesimpulan: pada remaja dengan obesitas, suplementasi vitamin E dengan 
dosis 400 IU selama 2 bulan tidak berpengaruh secara signifikan terhadap profil lipid dan kadar adiponektin 
Kata kunci: vitamin E, profil lipid, adiponektin, obesitas, uji klinis tersamar ganda.
ABSTRACT
Background: low-grade chronic inflammation in obese individuals contributes to the development of lipid 
abnormality and insulin resistance. Vitamin E has antioxidant and insulin-sensitizing properties, mediated 
by adiponectin. In this study, we aimed to evaluate the effect of vitamin E supplementation on lipid profiles 
and adiponectin levels in obese adolescents. Methods: this was a randomized, double-blind, controlled study. 
Obese adolescents aged 14-18 years, with no history of taking anti-obesity or antioxidant drugs, were recruited 
and randomized into two groups: vitamin E and placebo. The dose of vitamin E was 400 IU/day. Intervention 
was administered for two months. Lipid profiles and adiponectin levels were measured at baseline and after 
intervention. Primary outcomes were analyzed using the per-protocol analysis principle. Statistical analysis was 
performed using the independent t-test or the Mann-Whitney U test. Results: a total of 66 subjects completed the 
intervention study, 34 in the vitamin E group and 32 in the placebo group. Lipid profiles and adiponectin levels 
at 2 months after intervention did not differ significantly between the two groups. Changes from the baseline 
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levels were also not significantly different between the two groups and were inconsistent from one subject to 
another. Conclusion: in obese adolescents, vitamin E supplementation of 400 IU/day for 2 months does not 
significantly affect lipid profiles and adiponectin levels.
Keywords: vitamin E, lipid profiles, adiponectin, obesity, randomized controlled trial.
INTRODUCTION
Childhood obesity has become a critical 
issue in Indonesia. In line with the nation’s 
evolving economic situation, the prevalence of 
obesity is rising. On the other hand, malnutrition 
is also a persistent problem. This condition 
leads to what is called the “double burden of 
malnutrition”.1,2 Obesity is characterized by the 
presence of low-grade chronic inflammation 
that contributes to the development of metabolic 
syndrome and cardiovascular diseases later on.3 
Chronic inflammation leads to an increased 
production of reactive oxygen species (ROS) 
with ensuing damage to various organs.4 Obese 
adolescents are more likely to develop insulin 
resistance in adulthood compared to normal 
weight adolescents.3
Low-grade chronic inflammation in obese 
individuals is related to a reduction in their 
adiponectin levels. Adiponectin, also known as 
ACRP30 or AdipoQ, is an adipocytokine that is 
primarily secreted by adipose tissue.5 Increased 
adiponectin levels elicit a cascade that eventually 
results in an increased glucose uptake into cells 
and decreased gluconeogenesis.6-7 Additionally, 
adiponectin also plays an important role in 
increasing fatty acid oxidation and in lowering 
lipid peroxidation due to oxidative stress.8
Several studies have revealed multiple benefits 
of vitamin E in healthy individuals. Vitamin E is 
well-known as a potent lipid-soluble antioxidant 
involved in the prevention of lipid peroxidation 
within cell membranes. A previous study found 
that vitamin E supplementation of 400 IU/day was 
able to improve endothelial function in children.9
Vitamin E supplementation may increase 
adiponectin levels through various mechanisms. 
Vitamin E has anti-inflammatory properties, 
which may help in neutralizing low-grade 
chronic inflammation in obese individuals. 
Suppression of pro-inflammatory cytokines may 
lead to an increased production of adiponectin. 
Previous studies have found that vitamin E is 
similar in structure to ligands which bind to the 
peroxisome proliferator-activated receptor-γ 
(PPAR-γ). Thus, vitamin E administration 
activates the PPAR-γ-responsive promoter region 
in the adiponectin gene, resulting in increased 
expression of adiponectin.10-12
To date, there has been a paucity of data 
on the beneficial effects of vitamin E in obese 
children. Therefore, in this study, we aimed to 
evaluate the effect of vitamin E supplementation 
on the lipid profiles and adiponectin levels in 
obese adolescents.
METHODS
This was a randomized, double-blind, 
controlled study. The study was conducted at 
high schools in Central Jakarta from September 
2017 to February 2018. We chose this location 
due to its proximity to the Cipto Mangunkusumo 
Hospital. We included participants from twelve 
different high schools in this study.
Study Participants
Subject size was estimated using the formula 
for the mean difference between two independent 
populations, with type I error = 0.05 and power 
= 80 %. Pooled variance was calculated from 
previous studies.13,14 Mean changes of 0.8 µg/mL 
for adiponectin, 20 mg/dL for total cholesterol, 
10 mg/dL for LDL cholesterol, 5 mg/dL for HDL 
cholesterol, and 30 mg/dL for triglycerides were 
assumed as clinically significant. Based on the 
calculations, a minimum number of 31 subjects 
in each group was needed for this study. Obese 
adolescents aged 14-18 years were enrolled in 
this study. According to the Indonesian Guideline 
for Pediatric Nutrition Care, the term “obese” 
is defined as a body mass index (BMI) > 95th 
percentile in the CDC 2000 curve.15 Subjects 
were excluded if they consumed anti-obesity or 
antioxidant drugs.
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Randomization
Subjects were allocated into vitamin E 
and placebo groups using permutated block 
randomization with a size of four. An independent 
person who was not part of the study team 
placed either code A or code B into an envelope, 
which was then given to each subject. Code A 
was for placebo and code B was for vitamin E 
supplementation. The code list was concealed 
until the end of study. All study teams, subjects, 
and other related parties were blinded to the 
treatment allocation.
Intervention
The Indonesian Pediatric Society Guideline 
was basis of care for all subjects. Each subject 
received a capsule containing either vitamin 
E 400 IU or a placebo, which was consumed 
once daily. The placebo was made by the Cipto 
Mangunkusumo Hospital’s pharmacy unit 
and was identical in flavor and packaging to 
the vitamin E capsule. The subjects received 
intervention for two months.
To minimize the number of dropout subjects 
and to increase their compliance, we built a 
system (peer groups) using social media so that 
the subjects could remind each other to consume 
the capsules every day. We also distributed the 
capsules in two divided visits: at baseline and at 
one month of intervention. At the one-month and 
end-of-intervention visits, we asked the subjects 
to bring all the remaining capsules to assess their 
compliance.
Nutr i t ional  Consultat ion and Other 
Documentation
All selected subjects received a consultation 
from a nutritionist experienced in treating obese 
adolescents. Energy intake per day for each 
subject was determined using 24-h dietary recall. 
Each subject received information about daily 
energy requirements and the best dietary plan 
for treating obesity.
We documented the frequency of exercise per 
week but did not evaluate the type of exercise 
and the number of calories burned. We recorded 
every drug that was consumed by the subjects 
before and during the intervention.
Outcome Measurements
Subjects were required to fast for 12 hours 
before blood samples were collected for the 
measurement of lipid profiles and adiponectin 
levels. The lipid profile included triglycerides, 
total cholesterol (total-C), LDL cholesterol 
(LDL-C), and HDL cholesterol (HDL-C). 
Adiponectin levels were quantified using the 
Human Adiponectin ELISA Kit for Total and 
Multimers (Daiichi Pure Chemicals Co, Ltd.).
Statistical Analysis
Numeric data is presented in mean (SD) for 
normal data distribution, otherwise the data is 
presented in median (min-max). Outcome results 
were analyzed by the per-protocol analysis 
principle. Statistical analysis between groups 
was performed using the independent t-test, or 
the Mann-Whitney U test. We used the software 
SPSS ver 20.0 (IBM, Chicago, IL, USA) to 
analyze the data.
Ethical Statement
This study has been approved by the 
Ethical Committee of the Faculty of Medicine 
Universitas Indonesia - Cipto Mangunkusumo 
Hospital, with Ethical Approval Number 530/
UN2.F1/ETIK/2017.
RESULTS
We measured the body weights and the 
heights of 2,856 adolescents from twelve high 
schools around Jakarta. Based on their BMI 
values, only 148 adolescents were classified 
as obese. For this eligible study population, 
we provided information regarding obesity, 
performed anthropometry examination, and 
distributed informed consent and assent forms 
for the subjects and their parents. A total of 79 
adolescents was excluded from this study for 
various reasons, including: an unwillingness to 
participate, denial of permission by their parents, 
and obesity criteria not being met. The remaining 
69 adolescents were recruited as study subjects. 
We collected blood samples, provided them with 
nutritional counseling, and performed physical 
and anthropometric examinations. They were 
then randomized into two groups; 35 subjects 
were assigned to the vitamin E group and the 
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rest were assigned to the placebo group. In the 
vitamin E group, one subject withdrew from 
the study; in the placebo group, one subject was 
lost to the follow-up and one subject withdrew 
(Figure 1).
The median age of the 69 randomized 
subjects was 16.42 years, with the youngest 
and the oldest subjects aged 14 and 18 years, 
respectively. Mean BMI of all subjects was 
33.76 (3.41) kg/m2. Subjects in both the vitamin 
E and the placebo groups had similar baseline 
demographic characteristics, including age, 
body weight, body height, BMI, and waist 
circumference (Table 1).
Despite a higher value observed in the vitamin 
E group compared to the placebo group, the 
difference was not significant (Table 2).
Compared to the baseline, the changes in 
the lipid profiles and adiponectin levels after 2 
months of intervention did not differ significantly 
between the groups. The changes were also 
inconsistent from one subject to another in both 
groups (Table 3).
DISCUSSION
In this study, subjects in the two groups 
were comparable because they had similar 
baseline demographic characteristics, and 
they were all assigned by a double-blind 
randomization procedure. All subjects had a 
waist circumference ≥ 80, which indicates that a 
large amount of fat was distributed in their intra-
abdominal organs.16,17 Compared to subcutaneous 
fat, abdominal fat is more metabolically active 
and resistant to insulin. Visceral adipose tissue is 
known to actively produce free fatty acids (FFA) 
and adipocytokines, hence obese children with 
a high waist circumference are more at risk of 
Figure 1. Flow diagram of randomized controlled study







Age, years 16.12 (0.94) 16.84 (0.88)
Gender, n (%)
 - Male 21 (60) 22 (64.7)
 - Female 14 (40) 12 (35.3)
Body weight, kg 92.32 (8.88) 93.18 (15.9)
Body height, cm 165.27 (7.03) 165.91 (8.59)
BMI, kg/m2 33.82 (2.81) 33.7 (3.97)
Waist circumference, 
cm 104.06 (9.5) 105.32 (11.45)
Table 2. Lipid profiles and adiponectin levels at baseline and after 2 months
Variables
Baseline After 2 months
P value
Vitamin E (n=35) Placebo (n=34) Vitamin E (n=34) Placebo (n=32)
Triglyceridesa, mg/dL 115.5 (55-269) 117.5 (63-464) 112.5 (82-453) 132 (57-392) 0.426
Total-Cb, mg/dL 169 (29.05) 163.53 (30.73) 171.38 (29.61) 165.99 (28.57) 0.453
LDL-Cb, mg/dL 113.35 (26.13) 104.81 (29.49) 117.62 (28.4) 107.86 (27.32) 0.161
HDL-Cb, mg/dL 43.18 (7.64) 45.19 (10.35) 41.94 (7.06) 44.56 (9.87) 0.217
Adiponectina, µg/mL 3.16 (2.14-5.83) 3.38 (1.05-8.9) 4.18 (2.39-8.17) 4.13 (1.08-18.27) 0.423
a median (min-max), b mean (SD)
After 2 months of intervention, lipid profile 
parameters in both vitamin E and placebo groups 
were not significantly different. A similar result 
was also observed in the adiponectin levels. 
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developing metabolic syndrome.16-18
Current studies support the role of vitamin 
E in controlling lipid profiles owing to its 
antioxidant property. Compared to other plasma 
lipids, LDL is more easily oxidized by free 
radicals, forming oxidized LDL (oxLDL). This 
oxLDL has a high affinity for the macrophage 
scavenger receptor, resulting in fatty streak 
formation. HDL, on the other hand, plays a 
crucial role in buffering oxLDL by directly 
protecting the vascular wall and removing lipid 
hydroperoxide (LOOH) from oxLDL.19
In this study, we found that after 2 months 
of treatment, subjects in the vitamin E group had 
lower triglyceride and HDL levels but higher 
total-C and LDL-C levels compared to subjects 
in the placebo group. However, the differences 
between the two groups were not significant. 
Similarly, changes in the lipid profiles before 
and after intervention in the placebo and the 
vitamin E groups did not differ significantly. Our 
result supports previous studies.20-22 In apparently 
healthy adults, vitamin E administered in 
an escalating dose up to 400 mg/day (equal 
to 600 IU/day) for 21 days did not show a 
significant difference in lipid profiles pre- and 
post-intervention.20 A study of diabetes type 2 
subjects showed that the administration of 400 
IU of vitamin E twice a day for 3 months did 
not significantly change plasma lipid levels.21 
Another study in hemodialysis and peritoneal 
dialysis patients also reported similar results.22
The exact mechanism of adiponectin 
production is still unclear. Despite being secreted 
by many cells in the body, it is predominantly 
produced by adipocytes. Adiponectin is 
known to play an important role in energy 
homeostasis by improving insulin sensitivity, 
increasing fatty acid oxidation, and decreasing 
gluconeogenesis.23,24 It also shows antifibrotic 
properties by downregulating the expression of 
aldehyde oxidase and tissue growth factors.24-26 
In this study, we found that the adiponectin 
levels between the placebo and vitamin E groups 
at the end of the study were inconsistent and 
were not significant. The change in adiponectin 
levels before and after intervention was also not 
significantly different between the two groups. 
This inconsistent result may imply that the 
severity of chronic inflammation among obese 
individuals varies from one individual to another. 
A study involving overweight adults similarly 
found that vitamin E supplementation at 800 IU/
day for 6 months did not change adiponectin 
levels.13 One possible reason is a defect in 
adiponectin production. Vitamin E activates 
the promoter region of the adiponectin gene.10-
12 However, obesity causes DNA methylation 
of this gene, resulting in the suppression of 
adiponectin expression.27,28 Therefore, the 
expectation that vitamin E supplementation 
will increase the adiponectin levels higher than 
placebo is not realized. Obesity also lowers 
adiponectin receptor (AdipoR1) expression, 
leading to a state of adiponectin resistance.28,29 
A previous, double-blind, randomized 
controlled trial (RCT) study reported that vitamin 
E supplementation at a dosage of 400 IU/day for 
6 weeks was sufficient to improve endothelial 
function in children.9 However, our results 
did not support this finding as we found that 
supplementation with vitamin E at 400 IU/day for 
a longer duration did not change the adiponectin 
levels significantly. Mohammadi-Sartang M. 
et al.30 conducted a meta-analysis study to 
evaluate the role of vitamin E supplementation 




Vitamin E (n=34) Placebo (n=32)
Triglyceridesa, mg/dL 8 (-111 - 184) 21 (-71 - 250) 0.323
Total-Cb, mg/dL 2.38 (13.63) 2.43 (17.37) 0.989
LDL-Cb, mg/dL 4.26 (14.36) 3.06 (15.06) 0.741
HDL-Ca, mg/dL -1 (-9 - 6) 0 (-12 - 15) 0.557
Adiponectinb, µg/mL 1.33 (1.42) 1.18 (2.16) 0.742
a median (min-max), b mean (SD)
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(with or without other supplements) on plasma 
adiponectin levels. Their sub-group analysis 
results showed that a significant increase in 
adiponectin levels was found only in those trials 
that used a dose of vitamin E ≥ 400 mg/day (with 
or without other supplements) and had a duration 
of intervention of ≥ 6 months.30
Although the difference between the vitamin 
E and placebo groups was not significant in 
this study, the overall variable changes favored 
the vitamin E group. Compared to the placebo 
group, subjects in the vitamin E group had a 
smaller increase in triglyceride levels and a larger 
increase in adiponectin levels.
In clinical practice, the findings from this 
study imply that vitamin E supplementation 
may be beneficial for obese children. A higher 
dosage and longer duration of supplementation 
must be considered to produce more consistent 
effects. The results from this study may be 
used as a basis for further RCT studies. Studies 
using various dosages and durations of vitamin 
E supplementation and measuring low-grade 
chronic inflammation markers are necessary to 
comprehend the beneficial effects of vitamin 
E supplementation on adiponectin in obese 
children.
This study has several strengths and 
weaknesses. This was the first study in this 
field with adolescents as subjects. It was a 
randomized, double-blind, controlled study 
with similar baseline characteristics between the 
groups. The drawbacks of this study were the 
absence of controlled diets and activities.
CONCLUSION
Vitamin E supplementation of 400 IU/
day for 2 months does not significantly affect 
lipid profiles and adiponectin levels in obese 
adolescents. Further studies are necessary to 
comprehend the beneficial effects of vitamin E 
in obese adolescents.
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